Treatment of Atrioventricular Nodal Reentry Tachycardia (AVNRT)
A
Adam Kean, MD
Primary Investigator
Not Recruiting
21 years or below
All
Phase
N/A
30 participants needed
2 Locations
Brief description of study
The purpose of this study is to compare two techniques for identifying and treating a common type of arrhythmia, Atrioventricular Nodal Reentry Tachycardia (AVNRT), a condition which causes fast heart rates.
Detailed description of study
Researchers will randomize participants to undergo treatment for their AVNRT using one of the two techniques. There is an equal chance of being assigned to either group.
The main difference between the two procedures is the technique used to select the site of ablation for AVNRT. Both techniques are considered appropriate techniques to ablate AVNRT, but the best technique has not been determined.
If randomized to the traditional technique, participants' procedure will involve using the structure of the heart to select the site of ablation.
If randomized to the voltage and propagation wave technique, partipants' procedure will involve a common clinical procedure, which will also include gathering data from the heart tissue and the electrical wave that passes through the heart. This will be used to select the site of ablation.
Participants will complete follow-up visits around 2 months and around 1 year after the procedure. The follow-up at 2 months is standard for this institution and would have occurred regardless of participation in this study. The follow-up visit at 1 year will involve similar procedures but is being performed for research only.
Researchers will also contact participants by phone at 2 years to see how they are feeling.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Atrioventricular Nodal Reentry Tachycardia, AVNRT, Arrhythmia, Supraventricular Tachycardia, SVT
-
Age: 21 years or below
-
Gender: All
Individuals under 22 years of age with documented electrophysiologic (EP) evidence of AVNRT.
Individuals with moderate or severe complex congenital heart disease will not be eligible.
Updated on
01 Aug 2024.
Study ID: 1911034187, PCTR-UWISC-AVNRT-VOLTAGE
